Taiho Pharmaceutical Company Limited

Taiho Pahrmaceutical Co., Ltd.

Yu Kobayakawa

Fuyuki Yamamoto

Koji Ichikawa

Toshihiro Sakamoto

Yoshio Ogino

Tetsuya Sugimoto

Takashi Mizutani

Shoki Hara

Naoki Egashira

Hidefumi Kasuga

Hirokazu Fuchida

Takumitsu Machida

The present invention provides a novel compound inhibiting EGFR or a salt of the compound. According to one embodiment of the present invention, provided is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.

Substituted pyrrolo[2,3-d]pyrimidines as EGFR inhibitors

The invention of the present application provides a compound represented by Formula (I) or a salt thereof, which exhibits an inhibitory activity against at least one kinase selected from the group consisting of Akt kinase, Rsk kinase, and S6K kinase and/or a cell proliferation inhibiting effect and is useful as a prophylactic and/or therapeutic agent for diseases associated with the above-mentioned kinases, particularly cancer. [In the formula, Rrepresents a 4- to 6-membered monocyclic unsaturated heterocyclic group which has 1 to 3 hetero atoms independently selected from N, S and O and may have a substituent; Rrepresents a hydrogen atom or the like; R, R, and R, may be the same as or different from one another and independently represent a hydrogen atom or the like; Rrepresents a hydrogen atom or the like; Rand R, may be the same as or different from each other and independently represent a hydrogen atom or the like; Xand Xmay be the same as or different from each other and independently represent N or CR; Rrepresents a hydrogen atom or the like; and Xrepresents N or CH when the broken line () represents a single bond, and represents C when a broken line indicates a double bond, wherein at least one of Xor Xrepresents N.] 

5H-pyrrolo[2,3-D]pyrimidin-6(7H)-one derivative

Growing community of inventors

Ibaraki, Japan

Yu Kobayakawa